Health
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC – MedPage Today
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Neoadjuvant combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) produced a significant clinical benefit for patients with operable stage I-III non-small cell lung cancer (NSCLC), researchers reported.
The phase II NEOSTAR study randomly assigned 44 patients with operable NSCLC to neoadjuvant nivolumab with or without ipilimumab followed by surgery. Among those, 38% of patients that received the combination achieved major pathological response (MPR) — defined as 10% or less…
-
Business18 hours agoWarning! These ASX 200 shares were just downgraded
-
Business10 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News11 hours agoVegetables and herbs you can easily and cheaply grow from seeds
-
Business10 hours agoThis ASX 200 media stock is storming 7% higher to 52-week highs. Here’s why.